Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer

Yue Wang¹, Tianli Chen¹, Kangshuai Li¹, Wentao Mu¹, Zengli Liu¹, Anda Shi¹, Jialiang Liu¹, Wei Zhao¹, Shuo Lian¹, Shaohui Huang¹, Chang Pan² and Zongli Zhang¹*

¹ Department of General Surgery, Qilu Hospital, Cheelu College of Medicine, Shandong University, Jinan, China
² Department of Emergency, Qilu Hospital, Cheelu College of Medicine, Shandong University, Jinan, China

Biliary tract cancers (BTCs), including cholangiocarcinoma (CCA) and gallbladder cancer (GC), are malignancies originating from the biliary tract with poor prognosis. In the early stage of BTCs, surgery is the only choice for cure. Unfortunately, most patients with BTC are diagnosed at an advanced stage and lose the opportunity for surgery. For many advanced solid tumors, antiangiogenic therapy has achieved encouraging results. While most clinical studies on antiangiogenic therapy in advanced BTCs have shown an excellent disease control rate (DCR), the improvement in overall survival (OS) is controversial. Understanding how the relevant signaling molecules influence the angiogenic response and the functional interaction is necessary for the formulation of new treatment regimens and the selection of enrolled patients. In this review, we aim to summarize and discuss the latest advances in antiangiogenesis for BTCs, mainly focusing on the molecular mechanism of angiogenesis in BTCs and the therapeutic effects from clinical trials. Furthermore, the horizon of antiangiogenesis for BTCs is highlighted.

Keywords: angiogenesis, gallbladder carcinoma, biliary tract cancers, cholangiocarcinoma, targeted therapy, mechanism, antiangiogenic therapy

INTRODUCTION

Biliary tract cancers (BTCs) are a diverse group of malignancies originating in the biliary epithelium (1). According to their anatomical site of origin, BTCs are divided into cholangiocarcinoma (CCA) and gallbladder cancer (GC). CCAs are further classified as intrahepatic CCA (iCCA), perihilar CCA (pCCA), and distal CCA (dCCA) (2). PCCA and dCAA are also collectively called eCCA. BTCs account for only 3% of all gastrointestinal cancers, and the incidence of BTCs has increased over the past few decades (3). At present, surgical resection is still the only radical cure for BTCs (4).
However, because the symptoms of BTCs in the early stage are atypical, most cases are diagnosed at an advanced stage of disease and therefore lose the opportunity for radical surgical treatment. For patients with advanced unresectable or metastatic BTCs, systemic therapy might be the only beneficial treatment option (5). Unfortunately, due to the insensitivity to systemic therapies such as chemotherapy, the outcome of advanced and metastatic BTCs is unsatisfactory, with a 5-year survival rate of approximately 10%. Therefore, new therapies for BTC are urgently needed to improve the OS rate (6). In the era of precise treatment, antiangiogenic drugs are a main component of targeted therapy. However, the application of antiangiogenic therapy in BTC lacks consensus, and the criteria to select appropriate patients for antiangiogenic therapy have not been studied (7).

Metastasis is the main cause of individual death during tumor progression. There is sufficient evidence that tumor neovascularization is the pathological basis and necessary condition for the growth and metastasis of solid tumors (8). Tumor ischemia, on the one hand, affects the nutritional supply of the tumor, but on the other hand, it also impedes drug accessibility to the tumor and even promotes the selection of more aggressive tumor cells. Some scholars believe that promoting the normalization of tumor blood vessels will be an effective treatment (7).

Tumor-associated angiogenesis is active, and microvascular density is increased in BTCs, which contributes to the low cure and high recurrence rates after surgical resection. Microvessel density (MVD) is an indicator of tumor-driven neovascularization. MVD is significantly associated with survival and prognosis in GC, iCCA and extrahepatic cholangiocarcinoma (eCCA) (9–11). Studies confirmed that higher MVD was associated with advanced tumor stage and lower tumor resection rate and that MVD was an independent prognostic factor in a multivariate analysis. The 5-year survival rate of the high MVD group (2.2%) was significantly lower than that of the low MVD group (42.1%) (11), which suggested that the prognosis of BTCs is closely related to tumor angiogenesis. Although some antiangiogenic drugs have been approved for clinical trials in BTCs, the results are unsatisfactory. At present, the mechanism of tumor angiogenesis in BTCs is not clear, and the relevant targeted therapy needs to be further studied (12). This review summarizes the current consensus on tumor angiogenesis, with a focus on angiogenesis as the driving force in BTC development, and the status of the research and application of antiangiogenic therapy in BTCs.

**TUMOR ANGIOGENESIS AND TUMOR VASCULAR NORMALIZATION**

Tumor blood vessels are characterized by structural disorder, incomplete wall structure and high permeability, which can lead to local hypoperfusion of the tumor (13). Thus, it is difficult for either oxygen or drugs transported through blood vessels to enter the tumor parenchyma, which will greatly reduce the effectiveness of radiotherapy, chemotherapy and immunotherapy (14–16). The ionizing radiation of radiotherapy can locally produce reactive oxygen species (ROS) in the presence of oxygen. ROS can damage DNA and directly result in the death of tumor cells (17). However, the low-oxygen tumor microenvironment weakens the effect of this treatment. Systemic chemotherapy drugs need to attach to the local tumor area through the blood circulation system. A low perfusion state and increased interstitial pressure prevent drugs from attaching to the tumor area or reduce the amount of drugs entering the tumor parenchyma, thereby affecting the efficacy of chemotherapy. For the tumor itself, the lack of effective blood perfusion leads to a hypoxic tumor microenvironment (18). Hypoxia can activates the HIF (Hypoxia-inducible factor) signaling pathway, which promotes tumor cells to overexpress VEGF to induce tumor angiogenesis (19); In addition, tumor cells with more aggressive and metastatic ability will be screened out because of the harsh tumor microenvironment (20). The RhoA-ROCK1 signaling can be activated by HIF to enhance cell motility (21). Hypoxia increases hypermethylation of tumor suppressor gene, which makes epigenetic aberration and then promotes tumor growth and metastasis (22). Furthermore, hypoxia inhibits tumor immunity by inhibiting cytotoxic T cell activity, promoting local tumor recruitment of Treg cells, and inhibiting the synthesis of pro-inflammatory cytokines. These effects involve a series of factors including cAMP, HIF, COX2, SDF1, IL-10, etc. (23–26).

In the past, antiangiogenic therapy was thought to work by blocking the pathway of tumor angiogenesis and cutting off the nutrient supply to the tumor. However, with clinical research in recent years, it has been found that the effect of antiangiogenic therapy is limited, and some patients are more prone to tumor metastasis after antiangiogenic therapy (27). This is because antiangiogenic drugs severely degenerate tumor blood vessels, while blocking the nutritional supply of tumor, the supply of drugs and oxygen also been hindered. Such conditions can help tumor tissue resist the effects of radiotherapy and chemotherapy, and further deepen the hypoxia condition of tumor microenvironment (28). As mentioned above, hypoxia increases tumor malignant phenotype and inhibits tumor immunity, which is obviously not conducive to tumor therapy. Until the theory of tumor vascular normalization was proposed in 2005 (13), the purpose of antiangiogenic therapy has not changed from degrading tumor blood vessels to promoting the
maturation of tumor blood vessels, thereby improving local blood perfusion and material transportation in the tumor microenvironment. This notion partly addresses the limitations of antiangiogenic therapy and provides a theoretical basis for antiangiogenic therapy combined with chemotherapy or targeted therapy. After antiangiogenic treatment, there will be a specific time window. At this time, the tumor blood vessels will be temporarily and reversibly normalized, and drugs are easier to enter the tumor microenvironment (29).

Inhibition of tumor angiogenesis and induction of tumor vascular normalization are of great significance in the treatment of tumors (30). Unfortunately, the existing antiangiogenic therapies have not shown promising therapeutic effects, especially in the field of BTCs. Existing studies have shown that anti-VEGF therapy not only inhibits tumor angiogenesis, but also promotes normalization of tumor blood vessels (31). There are also reports showing that treatments targeting VEGF can increase the invasion and metastatic phenotype of tumors (32). These contradictory results are believed to be related to the complex regulatory network of tumor angiogenesis. Vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitors can mature tumor vessels by activating Tie-2 (33). Overexpression of proteins such as R-RAS and HRG which contribute to vascular maturation can normalize abnormal tumor vessels (34, 35). These findings provide new targets for tumor vascular normalization. In addition to the drug itself, the dose and duration of drugs are crucial for abnormal tumor vascular development to different outcomes, tumor vascular normalization and tumor vascular degeneration. While methods to assess the time window of tumor vessel normalization are still scarce, and the control of drug dose and time is not ideal (36). Furthermore, the mechanism of angiogenesis is ambiguous in tumors, and there are no therapeutic targets that can bypass normal blood vessels. Therefore, further research is needed to clarify the mechanism and explore more effective targets and treatment strategies (7).

FACTORS AND MECHANISMS THAT REGULATE ANGIOGENESIS IN BTCs

The growth of solid tumors is accompanied by tumor angiogenesis, and it is reasonable that anti-angiogenic therapy should be an important part of anti-tumor therapy. However, therapeutic regimens targeting VEGF/VEGFR have consistently failed to provide encouraging results (37). The main reasons is that there are many ways to promote angiogenesis (Figure 1). VEGF-dependent or VEGF-independent neovascularization and angiogenesis mimicry can all provide blood vessels for tumor tissues. Inhibition of one pathway leads to compensatory activation of other pathways. Besides, classical proangiogenic pathways, such as the VEGF/VEGFR pathway, also play a role in normal tissue. That makes treatment easier to be interrupted by on-target off-tumor toxicities (38). Therefore, it is critical to find tumor-specific antiangiogenic targets and the common pathways in different angiogenesis mechanisms. Understanding the pro- and anti-angiogenesis factors as well as their interaction and molecular mechanisms is essential for the development of durable and effective anti-angiogenesis drugs (39). In the following content, we will describe the role of pro-angiogenic and anti-angiogenic factors in BTCs, especially their regulatory mechanism.

VEGF/VEGFR SIGNALING PATHWAY

VEGF is a growth factor with the strongest angiogenic activity. The VEGF growth factor family includes VEGF-A, -B, -C, -D, -E, -F and placental growth factor (40). Among these types of VEGF, VEGF-A is generally believed to play the most obvious role in promoting angiogenesis. During mouse embryonic development, VEGF or VEGF receptor (VEGFR) gene deletion leads to embryonic death due to angiogenesis disorder. Additionally, VEGF plays an important role in tumor angiogenesis. VEGF is
overexpressed in many epithelial tumor cells. A large number of studies have reported that the level of VEGF in peripheral blood is directly related to tumor prognosis (41).

VEGF mainly acts through the corresponding receptors Flt-1 and KDR, also known as VEGFR-1 and VEGFR-2 (42). Both Flt-1 and KDR are receptors for tyrosine kinase receptors (RTKs). The binding of VEGF and KDR activates the MAPK signaling pathway and promotes endothelial cell proliferation and angiogenesis. The function of Flt-1 is more complicated. In addition to promoting angiogenesis, the combination of VEGF can also activate matrix metalloproteinases (MMPs). The increased expression of VEGF in tumor tissues is related to hypoxia-inducible factors, which can promote the expression of VEGF. The traditional concept states that VEGFR is specifically expressed in endothelial cells. However, an increasing number of recent studies have shown that tumor cells can also express VEGFR. VEGF secreted by tumor cells can promote angiogenesis and tumor cell proliferation through paracrine (acting on endothelial cells VEGFR) and autocrine (acting on the VEGFR of tumor cells) pathways.

Some researchers examined VEGF expression in four CCA cell lines and their culture supernatants. The results show that CCA cells can express and secrete VEGF (43). VEGF can be detected in bile and can be used as a diagnostic and predictive biomarker for different biliary diseases (44). Studies have shown that the positive expression rates of VEGF in clinical samples of iCCA, eCCA and GC are 53.8%, 59.2% and 56.3% (45–47). The overexpression of VEGF is related to the intrahepatic metastasis of iCCA (P=0.0224), while there was no significant correlation between VEGF and the clinical features of eCCA in this study (46). Other studies have shown that the expression of VEGF-A tends to increase in hypervascularized eCCA, but it did not reach statistical significance (P=0.08) (48). Further studies on eCCA have shown that, compared with pCCA, the positive expression rate of VEGF-A in dCCA is higher (69% vs. 25%, P <0.0001), and it is related to an increase in microvessel density (49). When VEGF was neutralized by adding 10 mg/mL anti-VEGF antibody to the medium, vascular endothelial cells decreased to 63.8% of the control group (P <0.02) (43). Any factor that destroys the expression of VEGF or VEGFR may affect the angiogenesis of BTCs. The following factors, hormones or drugs that may affect the VEGF signaling pathway were identified in the study of BTCs (Figure 2). TGF-β1 is expressed in tumor cells or surrounding mesenchymal cells, and immunostaining shows that its receptors TβR-I and TβR-II are strongly positively expressed in tumor cells. Studies have shown that TGFβ1 can promote the expression of VEGF in tumor cells through autocrine or paracrine modes and then affect tumor angiogenesis (50). S100A8 is highly expressed in CCA cells and increases the secretion of VEGF by activating the Toll-like receptor 4 (TLR4)/NF-κB pathway, thereby inducing the migration of vascular endothelial cells (51). Studies also show that COX-2 is related to angiogenesis. COX-2 is highly expressed in CCA tissues, especially advanced CCA (52). COX-2 inhibitors have been approved for adjuvant treatment of CCA, but in vitro experiments show that they have no inhibitory effect on the growth of tumor cells. COX-2 inhibitors can inhibit the expression and secretion of VEGF-C, thereby affecting the invasion of cholangiocarcinoma (52). MiR-101 can also inhibit COX-2 or directly target the 3’ untranslated region of VEGF mRNA to inhibit VEGF transcription (53). AKirin2 is overexpressed in CCA and promotes VEGF-A expression by activating the IL-6/STAT3 signaling pathway. This process can be inhibited by miR-490-3p (54). The highly conserved cell surface protein B7-H3 is reported to correlate with pathological rather than physiological angiogenesis and is regarded as an attractive target for the selective destruction of tumor vasculature (55). Estrogen can significantly increase the expression and secretion of VEGF-A in CCA cells. This effect is
partially inhibited by estrogen receptor antagonists and completely blocked when used in combination with IGF1-R blocking antibodies (56). Tumor necrosis factor-α (TNF-α) can promote or inhibit endothelial cell growth and angiogenesis, depending on the cell condition. Treatment with lupeol or stigmasterol significantly reduced the secretion of TNF-α in umbilical vein endothelial cells, and then, the transcription level of VEGFR-2 decreased, which interfered with tumor angiogenesis by inhibiting VEGF signaling (57). HMGB1 induces angiogenesis by promoting the expression of VEGF-2 in vascular endothelial cells (58). Histamine can increase the expression of VEGF-A/C. Histamine stimulation has an effect on the angiogenesis observed in the tumor microenvironment. This effect can be inhibited by the HDC inhibitor α-methyl-DL-histidine dihydrochloride or the H1HR antagonist terfenadine (59). In addition, a drug, phenformin, can increase the expression and secretion of VEGF (60).

VEGF also has a close relationship with precancerous lesions. There are stem cells called hepatic stem/progenitor cells (HPCs) around the biliary tree. In primary biliary cirrhosis (PBC), a precancerous lesion of CCA, HPC is activated, and VEGF-A and VEGF-C are highly expressed (61). Higher angiogenesis can be observed in PBC samples. These studies indicate that the VEGF/VEGFR signaling pathway and angiogenesis may play an important role in the occurrence and development of BTCs.

**PDGF/PDGFR SIGNALING PATHWAY**

The platelet-derived growth factor family (PDGF) regulates angiogenesis in tumors, and four family members have been identified, including PDGF-A, B, C, and D (62). PDGF can be synthesized and secreted by platelets, smooth muscle cells, vascular endothelial cells, pericytes and tumor cells. As a growth factor, PDGF combines with its receptor PDGFR to promote the growth of pericytes, vascular endothelial cells, fibroblasts, vascular smooth muscle cells and tumor cells by activating the Erk1/2 signaling pathway (63). PDGF promotes tumor cells migration by activating the p38/MAPK signalling pathway and overexpressing the MMPs. PDGF can also promote the directional migration and vascular envelopment of pericytes, thereby regulating the maturation and stability of tumor blood vessels. PDGF has been found to be highly expressed in a variety of solid tumors and as a predictor of poor prognosis. In biliary tumors, PDGF has been shown to be highly expressed and associated with poor prognosis (64, 65). Excessive activation of platelets has been found in CCA, which may be the source of PDGF in CCA (65). TCF-21 has been identified as a tumor suppressor gene in a variety of tumors, including CCA. When TCF-21 is overexpressed in CCA cells, it can inhibit the expression of PDGF (66).

**ANG-TIE-2 SIGNALING PATHWAY**

Another important group of angiogenesis regulators is the angiopoietin family, including Ang1 and Ang2, which act through their receptor Tie-2. In recent years, this family of proteins has received increasing attention (67). When VEGF-mediated angiogenesis is blocked, the upregulation of Ang expression has been shown to be part of the angiogenesis rescue response, leading to accelerated tumor metastasis. Ang1 and Ang2 have opposite effects. Ang1 is the agonist ligand Tie-2 (68), which activates downstream pathways after phosphorylation of the receptor, protects blood vessels, maintains endothelial cell survival, and inhibits inflammation and vascular leakage. Ang1 can be expressed in a variety of cells, such as pericytes, smooth muscle cells and fibroblasts. Ang2, which is mainly expressed in vascular endothelial cells, has the opposite effect as Ang1. Ang2 is an inhibitory ligand of Tie-2 that can block Ang1-induced Tie-2 activation. Ang2 can also destroy vascular stability and promote inflammation and leakage (69). Therefore, both Ang1 and Ang2 play important roles in vascular remodeling and angiogenesis (70).

Ang1 has been shown to be highly expressed in a variety of tumor cells. Tumor-associated endothelial cells express high levels of Ang2, and the Ang2 concentration in peripheral blood is thought to be related to the tumor progression of BTCs (71). The Tie-2 receptor has also been detected in the tumor vascular endothelium (68). Although reported to promote tumor growth, Ang1 usually exerts an antitumor effect. In a study of biliary tract tumors, a team found that the expression of Ang1 in pCCA was negatively correlated with the metastasis rate, and the presence of Tie-2-expanded monocytes (Tem) in tumor tissues was associated with a lower recurrence rate (70). Ang2 expression was correlated with higher MVD in CCA (P=0.015). When both Ang2 and VEGF are positive, the MVD of CCA tissue is significantly increased (45).

**BFGF/FGFR SIGNALING PATHWAY**

There are 22 members of the FGF family, from FGF-1 to FGF-23, except for FGF15 (human FGF19 and mouse FGF15 are homologous) (72). Among them, basic fibroblast growth factor (bFGF, also called FGF2) can affect vascular endothelial cells and stimulate angiogenesis. FGF receptor (FGFR) is expressed in endothelial cells. bFGF has been shown to be overexpressed in CCA (72, 73). Four CCA cell lines and their culture media were tested, and it was found that two of them can express and secrete bFGF, and all of them can express FGFR-1. The addition of anti-bFGF neutralizing antibody did not affect the proliferation of CCA cells but reduced the vascular endothelial cells to 58.9% of the control group (P<0.001). These results indicate that bFGF can affect the survival of the vascular endothelium in the form of paracrine signaling (43).

**APELIN/APLNR SIGNALING PATHWAY**

The apelin/APLNR axis plays important roles in regulating blood pressure and cardiovascular disease and in regulating angiogenesis and the endothelial cell response to hypoxia (74, 75). Studies have shown that high expression of apelin can
promote tumor angiogenesis in malignant tumors such as lung and liver cancers (76, 77). In CCA, researchers found that high expression levels of apelin and APLNR promote CCA cell proliferation and angiogenesis. Exogenous apelin stimulation can significantly increase the expression of angiogenesis factors (VEGF and Ang). Anti-APLNR reduces not only the expression of angiogenesis factors (VEGF and Ang) but also the expression of vimentin, MMP-9 and MMP-3 (78). These results suggest that the apelin/APLNR axis plays an important role in tumor angiogenesis. The mechanism regulating the expression of apelin/APLNR is not clear, but it has been extensively studied in different tumors. Apelin expression is related to oral squamous cell carcinoma hypoxia (79), and circulating apelin concentration is related to C-reactive protein in gastric and esophageal cancers (80). In prostate cancer, the level of apelin is regulated by microRNA-224 (81). Further research is needed in CCA.

OTHER FACTORS AND MECHANISM

MMP can degrade the extracellular matrix and promote tumor angiogenesis. The expression of MMP2/MMP9 is increased in CCA and associated with poor prognosis. The overexpression of PDGF can contribute to the overexpression of MMP2/MMP9 (65). The roles of TSP-1 in tumor angiogenesis and tumor progression are still controversial. The expression of TSP-1 is associated with a significant decrease in MVD levels in CCA (45), which suggests that TSP-1 may play a role in inhibiting angiogenesis in CCA. However, the incidence of intrahepatic metastasis is higher when TSP-1 is positive (45). In a study of iCCA, TSP-1 was also positively correlated with lymphatic invasion (82). LOXL1 is a classic member of the LOX family. It is overexpressed in iCCA and can be secreted outside the cell. LOXL1 protein can bind to the exposed RGD domain of FBLN5, then the complex can bind to Integrin alpha V beta 3 on the surface of vascular endothelial cells and promotes angiogenesis via the downstream FAK and MAPK signaling pathways (83). In addition, angiostatin and endostatin can also inhibit angiogenesis (84, 85). Recombinant human endostatin (ENDOSTAR) can act on a variety of cell signaling pathways. It reduces tumor angiogenesis-related proteins and inhibits tumor lymphangiogenesis to inhibit angiogenesis. Moreover, it has been shown to have a good therapeutic effect on nonsmall cell lung cancer (46). Recent studies have shown that recombinant human endostatin can bring clinical benefits to patients with advanced cervical cancer. However, the expression and role of angiostatin in CCA remain unclear. Integrins belong to the family of cell adhesion molecules and are involved in tumor angiogenesis. Multiple subtypes of integrin are highly expressed in BTCs (86, 87). Integrin as a receptor can promote endothelial cell migration by activating FAK and MAPK signaling pathways. Moreover, integrin on the surface of vascular endothelial cells can bind to a certain structure of the extracellular matrix to accelerate the migration of endothelial cells and the formation of tumor blood vessels (88). Cilengitide is an integrin antagonist that can recognize and interact with integrins. Their interaction induces tumor cell apoptosis and inhibits tumor angiogenesis (89). Thalidomide can also inhibit angiogenesis by blocking the secretion of VEGF and basic fibroblast growth factor (bFGF) (90).

Vasculogenic mimicry (VM) is a form of vessels that is different from vessels derived from classic tumor angiogenesis and is independent of the vascular endothelium (91). It is composed of a cord formed by aggressive and poorly differentiated tumor cells, through which blood can be seen (92). The pipeline is connected with the host’s blood vessels so that the tumor cells can obtain blood supply to meet the needs of tumor growth, invasion and metastasis (93). VM has been found in liver cancer, lung cancer, prostate cancer and ovarian cancer, and it has been proven to correlate with tumor growth, differentiation and invasion. However, there is still a lack of research in BTCs.

CLINICAL PROGRESS OF ANTIANGIOGENIC THERAPY IN BTCs

Anti-angiogenic drugs (Figure 3) are currently divided into three categories: anti-VEGF monoclonal antibodies such as bevacizumab; signaling pathway inhibitors, represented by the small molecule tyrosine kinase inhibitors; and recombinant human vascular endostatin (94). Bevacizumab monotherapy has been shown to be less effective. Long-term clinical studies have shown that bevacizumab monotherapy can prolong progression-free survival (PFS) but not overall survival (OS), suggesting that inhibition of the classic VEGF pathway may activate compensatory pathways that promote tumor angiogenesis or metastasis, thereby leading to a rebound in tumor malignancy. Small molecule multitargeted receptor tyrosine kinase (RTK) inhibitors such as sunitinib can simultaneously suppress multiple signaling pathways (95). This effect is expected to solve the problems of the abnormal activation of other signaling pathways in the case of a single inhibition of VEGF signaling pathways. Although TKI drugs, including sorafenib, axitinib, and sunitinib, are all multitarget inhibitors, their effects are mostly the same (96, 97). For example, the main targets of axitinib are VEGFR-1, VEGFR-2, VEGFR-3, the role of those are mainly angiogenesis (98). The inhibitory effect is not obvious on the target of whose roles are mainly promoting tumor cell survival and proliferation. Besides, these small molecule tyrosine kinase inhibitors have minimal effect on the tumor microenvironment. To improve the efficacy, on the one hand, a combination of drugs can be applied to interfere with angiogenesis and tumor proliferation simultaneously; on the other hand, a new generation of antiangiogenic drugs should cover more targets involved in the tumor growth. Anlotinib, as a new generation of antiangiogenic drugs, can inhibit tumor angiogenesis by targeting VEGFR, FGFR and PDGFR, meanwhile, it can also inhibits tumor growth by targeting c-kit (99). The significantly prolonged PFS and OS achieved in anlotinib treated drug-resistant NSCLC patients may be due to this dual effect (100). Currently, angiogenesis-based drug
strategies for the treatment of malignant tumors include single-drug therapies with targeted drugs, combinations of chemotherapy and targeted drugs, combinations of immunotherapy and targeted drugs, and combined applications of targeted drugs. At present, antiangiogenic therapy has not been approved for the clinical treatment of biliary tract tumors, and most of the relevant studies are in the clinical trial stage. The following will summarize the research progress of antiangiogenic therapy for biliary tumors (Table 1).

MONOTHERAPY REGIMENS

The single-drug regimens of antiangiogenic therapy mostly use signaling pathway inhibitors, which can act on multiple targets simultaneously. Although more targets can increase the efficacy, the possibility of the corresponding side effects is also increased. Sunitinib, a multtarget tyrosine kinase inhibitor that targets PDGFR, VEGFR, KIT, FLT-3 and RET, can inhibit not only tumor proliferation but also angiogenesis at the same time. Sunitinib has been shown to be effective in the treatment of several solid tumors. In a study of advanced biliary tract tumors, Jun Ho Yi et al. believed that sunitinib monotherapy had a poor clinical effect. The PFS was only 1.7 months, and the incidence of grade 3–4 toxicities was high (46.4%) (101). Dreyer C et al. reported three cases of ICC patients with tumor progression after receiving first-line chemotherapy and treated them with sunitinib. Reductions in tumor size and density were observed in all three cases; one achieved partial remission, and two achieved stable disease (SD). They concluded that sunitinib was well tolerated and had manageable side effects. Based on these encouraging results, they initiated a phase II clinical study of sunitinib for second-line treatment in patients with advanced intrahepatic cholangiocarcinoma who had received chemotherapy (102). Fifty-three patients were included in this study, of whom 15% achieved partial remission, 71% achieved disease stability, the median PFS (mPFS) was 5.2 months and the median OS (mOS) was 9.6 months [95% CI: 5.8–13.1] (103). Thus, sunitinib monotherapy shows promising activity in advanced intrahepatic cholangiocarcinoma. Sorafenib, a hot multitarget tyrosine kinase inhibitor that targets VEGFR-2/-3, PDGFR-B, B-Raf, and C-Raf, achieved a 2% disease remission rate in the second-line treatment of 46 patients with advanced cholangiocarcinoma. The median progression-free survival was 2.3 months (range: 0–12 months), and the median overall survival was 4.4 months (range: 0–22 months) (104). Another study using sorafenib as a first-line regimen for advanced biliary tumors showed that the median PFS was 3 months (95% CI: 2–4 months) and the median OS was 9 months (95% CI: 4–12 months) (105). The results of these two clinical trials indicate that sorafenib did not achieve positive results in the treatment of advanced biliary tumors as a Monotherapy, and the combination therapy of sorafenib with other drugsit may be a promissing future direction. Lenvatinib is an inhibitor of VEGFR, FGFR and PDGFR. A phase II clinical trial was conducted with lenvatinib as a single agent for advanced biliary tract tumors. An interim evaluation of 17 patients showed a DCR of 82% (106). Finally, 26 patients were recruited into the study, and the results showed that the median PFS was 3.19 months (95% CI: 2.79–7.23) and the median OS was 7.35 months (95% CI: 4.50–11.27). Therefore, the study authors concluded that lenvatinib showed promising therapeutic effects in advanced biliary tract tumors with manageable side effects (107). Regorafenib is a multitarget inhibitor that targets VEGFR, PDGFR-β, KIT, RET and RAF-1. For patients with advanced biliary tract tumors who received failing first-line treatment, the average progression-free survival
| Therapy | Target | NCT | Line | Phase | n | Patients | mPFS/mTTP months (95% CI) | mOS months (95% CI) | ORR | DCR |
|---------|--------|-----|------|-------|---|----------|--------------------------|---------------------|-----|-----|
| **monotherapies** | | | | | | | | | | |
| Sorafenib | VEGFR, PDGFR, Raf | NCT 00238212 | first | II | 31 | advanced BTC | 3.0 (2.0-4.0) | 9.0 (4.0-12.0) | 0.0% | 39.0% |
| Sunitinib | VEGFR, PDGFR, c-Kit, IRE1α | NCT 01718327 | second | II | 53 | advanced iCCA | 5.2 | 9.6 (5.8-13.1) | 15.0% | 85.0% |
| Sunitinib | VEGFR, PDGFR, c-Kit, IRE1α | NCT 01082809 | second | II | 56 | advanced BTC | 1.7 (1.0-2.4)* | 4.8 (3.8-4.8) | 8.9% | 50.0% |
| Lenvatinib | VEGFR, FGFR, PDGFR, Kit, RET | NCT 02579616 | second | II | 17 | advanced BTC | 3.2 (2.7-7.23) | 7.4 (4.5-11.3) | 11.5% | 85.0% |
| Lenvatinib | VEGFR, FGFR, PDGFR, Kit, RET | NCT 02579616 | second | II | 26 | advanced BTC | 3.9 (3.2-6.2) | 8.0 (3.3-18.6) | 11.0% | 56.0% |
| Regorafenib | VEGFR, PDGFR, Kit, RET, Raf | NCT 0253376 | second | II | 43 | advanced BTC | 3.2 (2.7-5.1) | 8.3 (3.8-12.9) | 20.8% | 62.5% |
| Apatinib | VEGFR-2 | NCT 03521219 | second | II | 24 | advanced iCCA | 2.3 (0.7-3.3) | 9.0 (4.6-13.4) | 15.5% | 50.3% |
| Vandetanib | VEGFR, FGFR, PDGFR, Tie-2, FGFR | NCT 00753675 | first | II | 56 | advanced BTC | 3.4 (2.3-5.0) | 7.4 (6.1-11.7) | 3.6% | 25.0% |
| **Cytotoxic + targeted therapies** | | | | | | | | | | |
| GEM+ | VEGFR, EGFR, | NCT 00753675 | first | II | 57 | advanced BTC | 3.7 (2.9-6.2) | 9.2 (6.9-11.6) | 19.3% | 29.8% |
| Vandetanib | PDGFR, Tie-2, FGFR | | | | | | | | | |
| GC+ | VEGFR, PDGFR, Raf | NCT 00919061 | first | II | 39 | advanced BTC | 6.5 (3.5-8.3) | 14.4 (11.6-19.2) | 13.5% | 20.0% |
| Sorafenib | VEGFR, PDGFR, Raf | NCT 01007552 | first | II | 50 | advanced BTC | 8.1 (5.3-9.9) | 10.2 (7.5-13.7) | 24.0% | 72.0% |
| GemCap+ | VEGF | NCT 00361231 | first + second | II | 35 | advanced BTC | 7.0 (5.3-10.3) | 12.7 (7.3-18.1) | 40.0% | 69.0% |
| Bevacizumab | VEGF | | | | | | | | | |
| GEM+ | VEGFR, EGFR, | | | | | | | | | |
| L-OHPL+ | Cape+Panitumumab | | | | | | | | | |
| GEM+L-OHPL+ | Cape+Bevacizumab | | | | | | | | | |
| GEM+placebo | VEGFR, PDGFR, RAF, KIT, FLT-3 | NCT 00661830 | first | II | 36 | advanced BTC | 4.9 (3.5-7.7) | 11.2 | 10.0% | 90.0% |
| GEM+Sorafenib | VEGFR, PDGFR, Raf, Kit, FLT-3 | NCT 00939848 | first | II | 41 | advanced BTC | 3.0 (1.8-7.2) | 8.4 | 14.0% | 88.0% |
| GC+ | VEGFR, PDGFR, c-kit | NCT 03895970 | second | II | 62 | advanced BTC | 7.4 (5.7-8.5) | 11.9 (9.2-14.3) | 19.0% | 65.0% |
| Bevacizumab | VEGF | | | | | | | | | |
| GEM+placebo | VEGFR, PDGFR, Raf, Kit, FLT-3 | NCT 03895970 | second | II | 32 | advanced BTC | 4.9 (4.7-5.2) | 11.0 (9.6-12.3) | 25.0% | 78.1% |
| GC+Bevacizumab | VEGFR, PDGFR, Raf, Kit, FLT-3, EGFR | NCT 01093222 | first | II | 34 | advanced BTC | 2.0 (2.0-3.0) | 6.0 (3.0-8.0) | 6.0% | 35.0% |
| Targeted + targeted therapies | | | | | | | | | | |
| Lenvatinib+ | VEGFR, FGFR, PDGFR, Kit, RET, PD-1 | NCT 00356889 | first | II | 49 | advanced BTC | 4.4 (3.0-7.8)* | 9.9 (7.2-13.6) | 12.0% | 63.0% |

*These data represent mTTP.

GEM, Gemcitabine; GC, Gemcitabine + Cisplatin; GemCap, Gemcitabine + Capecitabine; GEMOX, Gemcitabine + Oxaliplatin; L-OHPL, Oxaliplatin; Cape, Capecitabine; NCT, National Clinical Trial; mPFS, median progression-free survival; mTTP, median time to progression; mOS, median overall survival; ORR, objective response rate; DCR, disease control rate.
of regorafenib treatment was 3.9 months (95% CI: 3.2–6.2), and the average overall survival time was 8 months (95% CI: 3.3–18.6). Regorafenib may exert its promising efficacy in advanced biliary tract tumors, which is worthy of further study (108).

COMBINATION THERAPY REGIMENS

Chemotherapy Combined With Targeted Therapy

A phase II study of bevacizumab combined with gemcitabine/capecitabine in the treatment of advanced BTCs showed that the mPFS was 8.1 months, and the mOS was 10.2 months. Compared with the results of the gemcitabine/cisplatin combination in the ABC-02 trial (8 months of PFS and 11.7 months of OS), it could not be concluded that bevacizumab combined with Gemcitabine plus Capecitabine (GemCap) would benefit patients. However, more clinical stage IV patients were enrolled in the former group than in the latter group, and the proportion of patients with stage III disease was relatively low (6% vs. 25%) (109). Gemcitabine plus Oxaliplatin (GEMOX) in BTCs achieved an ORR of 26%-50% and a median overall survival of 11–12 months. The ORR of Gemox-B (the addition of bevacizumab to GEMOX) in BTCS reached 40%, the median progression-free survival reached 7.0 months, and the median overall survival reached 12.7 months (110). A phase II clinical trial showed that after two treatment cycles of bevacizumab combined with gemcitabine and oxaliplatin, the maximum standardized uptake value on FDG-PET scans was significantly decreased, indicating disease control and longer PFS and OS (110). A phase II clinical trial of the multtarget tyrosine kinase inhibitor cediranib combined with first-line chemotherapy in the treatment of advanced biliary tract cancer was conducted. Patients were randomly divided into two groups: cediranib combined with chemotherapy or placebo combined with chemotherapy. However, only ORR but not mPFS or mOSz showed a statistically significant difference, with 44% in the cediranib group versus 19% in the placebo group (111). In addition, sorafenib has also been introduced into several clinical trials of combination therapy regimens. However, the strategy of sorafenib combined with gemcitabine and cisplatin failed to improve the efficacy (112). Another trial on sorafenib combined with gemcitabine versus gemcitabine combined with placebo showed that the addition of sorafenib did not improve the outcome of advanced biliary tumors (113). Vandetanib is also a kinase inhibitor that has been shown to inhibit angiogenesis in vivo and in vitro. The efficacy and side effects of vandetanib as a monotherapy, vandetanib combined with gemcitabine and gemcitabine combined with placebo were studied. There was no difference in side effects among the three groups, while the objective response rate (ORR) of the vandetanib combined with gemcitabine group was higher than those of the other two groups (114). The efficacy of chemotherapy combined with EGFR inhibitor and VEGF monoclonal antibody was also studied, and the results showed no significant difference in mOS and mPFs between the GEM + L-OHPL + CAPE + panitumumab group and the GEM + L-OHPL + CAPE + bevacizumab group, although the former group had a higher ORR (115). From the results above, a conclusion can be drawn that cytotoxic drugs combined with anti-angiogenic drugs may achieve a better ORR in patients with BTCs, although little improvements in mPFS and mOS was observed.

Combination Therapy With Multiple Targeted Drugs

A phase II multicenter clinical trial of bevacizumab and erlotinib (an EGFR tyrosine kinase inhibitor) showed that 12% of patients had a confirmed partial response, 51% achieved stable disease, the median TTP was 4.4 months (95% CI: 3.0–7.8), and the median overall survival was 9.9 months (95% CI: 7.2–13.6) (116). Another clinical trial recruited 32 patients who were pretreated with systemic antitumor treatments to receive treatment with pembrolizumab combined with lenvatinib. The ORR of all patients was 25%, the median OS was 11.0 months (95% CI: 9.6–12.3), and the median PFS was 4.9 months (95% CI: 4.7–5.2) (117). Furthermore, a phase II SWOG study with sorafenib and erlotinib for advanced cholangiocarcinoma yielded a median progression-free survival of 2 months (95% CI: 2–3 months) and a median overall survival of 6 months (95% CI: 3–8 months) (118). The combination of multiple targeted drugs as an alternative strategy for advanced BTCs has preclinical evidences. The activity of this combination has been verified in some clinical trials, Although, the improvement in OS or PFS should be investigated by further clinical trials.

DISCUSSION

Biliary tract tumors account for 3% of all digestive tract tumors. Their incidence has been increasing in recent years for various reasons (119). Therefore, it is urgent to increase the treatment selection of BTCs (120, 121). The development of individualized treatment plans is of great significance for cholangiocarcinoma with high heterogeneity (122, 123). The clinical trial results revealed that most antiangiogenic drugs alone or in combination did not significantly prolong OS and PFS in patients with biliary tract tumors. However, some of these clinical trials achieved considerable ORR, indicating significant tumor regression at the early stage of treatment. There are two possible reasons for the unsatisfactory results of antiangiogenic therapy. On the one hand, a compensatory feedback pathway may be activated when one angiogenesis pathway is inhibited. For example, inhibiting VEGF signaling pathways may activate Ang pathways. On the other hand, inhibition of angiogenesis leads to hypoxia in the local environment, which may promote the expression of tumor proliferation and migration genes. For example, HIF-1 and downstream gene expression levels were increased after VEGF inhibition. Therefore, combination therapy as the future direction of antiangiogenic therapy seems to be feasible. The combination of the antiangiogenic drug bevacizumab and the antiproliferative drug acetazolamide results in tumor inhibition in mice (124). Further clinical
studies should be performed in the future to test this hypothesis. Based on the theory that antiangiogenic agents help target drugs penetrate into the tumor microenvironment, the effect of pemigatinib, a novel drug, which is approved by the FDA for the treatment of cholangiocarcinoma, in combined with should also be investigated for the treatment of patients with FGFR mutations.

The selection of potential patients who will benefit from antiangiogenic drugs is also crucial for the design of clinical trials and may be a critical factor for reaching the main endpoint. Dreyer et al. reported promising results in three iCCA patients who were selected with hypervascular features. Therefore, the selection of cases with active tumor angiogenesis through imaging or histological evaluation may be conducive to improving the ORR. Some researchers have confirmed that the DWI phase of MRI is effective in evaluating tumor angiogenesis (125). Wu Xin et al. analyzed 88 cases of eCCA and found that ADC values were negatively correlated with MVD and VEGF (p < 0.05), indicating that DWI could be performed for the selection of BTCs who may benefit from antiangiogenic treatment. It is critical to find more useful methods and markers to help clinicians assess whether patients can benefit from antiangiogenic therapy before medication.

At present, in clinical studies, RECIST is mostly applied to evaluate the effect of antiangiogenic therapy. However, antiangiogenic treatment may not result in a significant change in tumor volume in BTCs. After vascular degeneration, the interior of the tumor is necrotic, and the volume may not change. Therefore, traditional RECIST is not appropriate to evaluate the efficacy. Some researchers have proposed new ways to assess efficacy. It has been suggested that activated circulating vascular epithelial cells (aCECs) have higher sensitivity and reliability in efficacy evaluation than upstream factors such as VEGF. Some scholars have proposed using intratumor blood perfusion indicators [such as blood flow (BF) and blood volume (BV)] to reflect changes in blood supply. In particular, in view of the theory of vascular normalization proposed in recent years, how to evaluate the time window of anti-vascular therapy has become an urgent problem.

There are many kinds of cells in the tumor microenvironment, and the cytokines secreted and the receptors expressed by them constitute multiple signaling pathways that interact with each other. These signaling pathways are involved in tumor angiogenesis (126). Inhibition of one target or one pathway may result in short-term tumor regression, but inhibition of one pathway may promote another pathway. Therefore, effective antiangiogenic therapy needs to focus on common targets or multiple targets of multiple pathways and solve drug delivery problems in the leaky and poorly perfused tumor microenvironment. The study of improving the mechanism of angiogenesis in cholangiocarcinoma is helpful to find new therapeutic targets. Strengthening the construction of methods to evaluate tumor vascular normalization is helpful for the clinical development of reasonable antivascular therapy.

In conclusion, as highly heterogeneous tumors, the treatment and management of BTCs needs comprehensive evaluation and individualized medication, for which antiangiogenic therapy is a promising treatment method.

**AUTHOR CONTRIBUTIONS**

YW collected and analyzed the previous research fruits, and wrote the manuscript. TC, KL, and WM modified this article. ZL, AS, JL, WZ, SL, SH and CP contributed to the search for literature. ZZ designed and supervised the review. All authors contributed to the article and approved the submitted version.

**FUNDING**

Our study was supported by Shandong University Multidisciplinary Research and Innovation Team of Young Scholars (Grant No. 2020QNQT002), National Natural Science Foundation of China (Grant No. 82072676, 82172791), China Postdoctoral Science Foundation (Grant No. 2020M682190, 2020M682195), Clinical Research Foundation of Shandong University (Grant No. 2020SDUCRA018), Natural Science Foundation of Shandong Province (ZR2019MH008), Jinan City Science and Technology Development Program (Grant No. 201805017, 201805013), Clinical Research Innovation Fund Project (CXPJ[H]180001-2018240), Hengrui Hepatobiliary and Pancreatic Foundation (Grant No.Y-2017-144), and Beijing Medical Award Foundation (YXJL-2020-0785-0967, YXJL-2020-0785-0968).

**REFERENCES**

1. Labib PL, Goodchild G, Pereira SP. Molecular Pathogenesis of Cholangiocarcinoma. *BMC Cancer* (2019) 19(1). doi: 10.1186/s12885-019-3391-0

2. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary Tract Cancer. *Lancet* (2021) 397(10272):428–44. doi: 10.1016/S0140-6736(21)00153-7

3. Banales JM, Cardinale V, Carpio G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert Consensus Document: Cholangiocarcinoma: Current Knowledge and Future Perspectives Consensus Statement From the European Network for the Study of Cholangiocarcinoma (ENS-CCA). *Nat Rev Gastroenterol Hepatol* (2016) 13(5):261–80. doi: 10.1038/nrgastro.2016.51

4. Marin JG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, et al. Current and Novel Therapeutic Opportunities for Systemic Therapy in Biliary Cancer. *Br J Cancer* (2020) 123(7):1047–59. doi: 10.1038/s41416-020-0987-3

5. Banales JM, Marin JG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: The Next Horizon in Mechanisms and Management. *Nat Rev Gastroenterol Hepatol* (2020) 17(9):557–88. doi: 10.1038/s41575-020-0310-z

6. Chen T, Li K, Liu Z, Liu J, Wang Y, Sun R, et al. WDR5 Facilitates EMT and Accumulation in Myc-Dependent Metastasis of CCA by Increasing HIF-1α Accumulation in Myc-Dependent and Independent Pathways. *Mol Ther* (2021) 29(6):2134–50. doi: 10.1016/j.ymthe.2021.02.017

7. Viallard C, Larriuffe B. Tumor Angiogenesis and Vascular Normalization: Alternative Therapeutic Targets. *Angiogenesis* (2017) 20(4):409–26. doi: 10.1007/s10456-017-9562-9

8. Folkman J. Tumor Angiogenesis: Therapeutic Implications. *N Engl J Med* (1971) 285(21):1182–6. doi: 10.1111/1523-1747.ep12625746
26. Lequeux A, Noman MZ, Xiao M, Van Moer K, Hasmim M, Benoit A, et al.

27. Vasudev NS, Reynolds AR. Anti-Angiogenic Therapy for Cancer: Current Progress, Unresolved Questions and Future Directions. Angiogenesis (2014) 17(3):471–94. doi: 10.1007/s10456-014-9420-y

28. Seton-Rogers S. When Good Drugs do Bad Things. Nat Rev Cancer (2009) 9(4):228–9. doi: 10.1038/nrc2632

29. Jain RK. Normalizing Tumor Vasculature With Anti-Angiogenic Therapy: A New Paradigm for Combination Therapy. Nat Med (2001) 7(9):987–9. doi: 10.1038/nm0901-987

30. Chen P, Bonaldo P. Role of Macrophage Polarization in Tumor Angiogenesis and Vessel Normalization: Implications for New Anticancer Therapies. Int Rev Cell Mol Biol (2013) 301:1–35. doi: 10.1016/B978-0-12-407704-1.00001-4

31. Carmelit p, Jain RK. Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases. Nat Rev Drug Discov (2011) 10(6):417–27. doi: 10.1038/nrd3455

32. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated Metastasis After Short-Term Treatment With a Potent Inhibitor of Tumor Angiogenesis. Cancer Cell (2009) 15(3):232–9. doi: 10.1016/j.ccr.2009.01.021

33. Kontos CD, Willett CG. Inhibiting the Inhibitor: Targeting Vascular Endothelial Protein Tyrosine Phosphatase to Promote Tumor Vascular Maturation. J Natl Cancer Inst (2013) 105(16):1163–5. doi: 10.1093/jnci/djt199

34. Rolny C, Mazzone M, Tugues S, Laouidi O, Johansson I, Coulon C, et al. HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization Through Downregulation of PI3K/GSK3B. Cancer Cell (2011) 19(1):31–44. doi: 10.1016/j.ccc.2010.11.009

35. Sawada J, Uramaki T, Li F, Uramaki A, Zhu W, Fukuda M, et al. Small GTPase RhoB Regulates Integrity and Functionality of Tumor Blood Vessels. Cancer Cell (2012) 22(2):235–49. doi: 10.1016/j.ccc.2012.06.013

36. Li W, Quan YY, Li Y, Lu C, Cui M, et al. Monitoring of Tumor Vascular Normalization: The Key Points From Basic Research to Clinical Application. Cancer Manag Res (2018) 10:4163–72. doi: 10.2147/CMAR.S174712

37. Abdalla A, Xiao L, Ullah MW, Yu M, Ouyang C, Yang G. Current Challenges of Cancer Anti-Angiogenic Therapy and the Promise of Nanotherapeutics. Theranostics (2018) 8(2):533–48. doi: 10.7150/thno.21674

38. Mukherjee A, Madamssetty VS, Paul MK, Mukherjee S. Recent Advancements of Nanomedicine Towards Antiangiogenic Therapy in Cancer. Int J Mol Sci (2020) 21(2). doi: 10.3390/ijms21020455

39. Huang D, Lan H, Liu F, Wang S, Chen X, Jin K, et al. Anti-Angiogenesis or Pro-Angiogenesis for Cancer Treatment: Focus on Drug Distribution. Int J Clin Exp Med (2015) 8(6):8369–76.

40. Dai J, Rabie AB. VEGF: An Essential Mediator of Both Angiogenesis and Endoconchial Ossification. J Dent Res (2007) 86(10):937–50. doi: 10.1177/154082210708601006

41. Lange C, Storkebaum E, de Almodovar CR, Dewerchin M, Carmelit P. Vascular Endothelial Growth Factor: A Neurovascular Target in Neurological Diseases. Nat Rev Neurol (2016) 12(6):439–54. doi: 10.1038/

42. Shibuya M. VEGF/VEGFR System as a Target for Suppressing Inflammation and Other Diseases. Endoc Metab Immune Disord Drug Targets (2015) 15(2):135–44. doi: 10.2147/EMT.S21674

43. Ogasawara S, Yano H, Higaki K, Takayama A, Akiba J, Shiota K, et al. Expression of Angiogenic Factors, Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor, in Human Biliary Tract Carcinoma Cell Lines. Hepatol Res (2001) 20(1):97–113. doi: 10.1046/s1386-6346(00)00117-0

44. Navaneethan U, Gutierrez NG, Jegadesan R, Venkatesh PG, Poptic E, Liu X, et al. Vascular Endothelial Growth Factor Levels in Bile Distinguishes Pancreatic Cancer From Other Etiologies of Biliary Stricture: A Pilot Study. Dig Dis Sci (2013) 58(10):2986–92. doi: 10.1007/s10620-013-2764-0

45. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, et al. Angiogenesis in Cholangiocellular Carcinoma: Expression of Vascular Endothelial Growth Factor, Angiopoietin-1/2, Thrombospondin-1 and Clinicopathological Significance. Oncol Rep (2006) 15(3):523–32. doi: 10.3892/or.15.3.525

46. Yoshikawa D, Ojima H, Iwakoa N, Kosuge TK. Clinicopathological and Prognostic Significance of EGFR, VEGF, and GERP3 Expression in Cholangiocarcinoma. Br J Cancer (2008) 99(2):418–25. doi: 10.1038/sj.bjc.6604129

47. Sun XN, Cao WG, Wang X, Wang Q, Gu BX, Yang QC, et al. Prognostic Impact of Vascular Endothelial Growth Factor-A Expression in Resected
Wang et al. Antiangiogenic Therapy in BTCs

Gallbladder Carcinoma. *Tumour Biol* (2011) 32(6):1183–90. doi: 10.1007/s13277-011-0221-2

Mobius C, Dethmar C, Aigner T, Wiedmann M, Wittekind C, Mössner J, et al. Evaluation of VEGF A Expression and Microvascular Density as Prognostic Factors in Extrahepatic Cholangiocarcinoma. *Eur J Surg Oncol* (2007) 33(8):1025–9. doi: 10.1016/j.ejso.2007.02.020

Guend J, Zhan Q, Perigny M, Rautou PE, Degos F, et al. Comparative Protein Expression Profiles of Hilar and Perihilar Hepatic Cholangiocarcinomas. *J Hepatology* (2009) 51(3):119–101. doi: 10.1016/j.jhep.2009.03.017

Bencert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, et al. Transforming Growth Factor Beta 1 Stimulates Vascular Endothelial Growth Factor Gene Transcription in Human Cholangiocellular Carcinoma Cells. *Cancer Res* (2003) 63(5):1083–92.

Pan S, Hu Y, Hu M, Xu Y, Chen M, Du C, et al. S100A8 Facilitates Angiogenesis in Cholangiocarcinoma Metastasis via Upregulation of VEGF Through TLR4–NF-κB Pathway Activation. *Int J Oncol* (2020) 56(1):101–12. doi: 10.3892/ij o.2020.4977

You Z, Bei L, Cheng LP, Cheng NS. Expression of COX-2 and VEGF-C in Cholangiocarcinomas at Different Clinical and Pathological Stages. *Gut Mol Res* (2015) 14(2):6239–46. doi: 10.4238/2015.June.9.9

Zhang J, Han C, Zhu H, Song K, Wu T. miR-101 Inhibits Cholangiocarcinoma Angiogenesis Through Targeting Vascular Endothelial Growth Factor (VEGF). *Am J Pathol* (2013) 182(5):1629–39. doi: 10.1016/j.ajpath.2013.01.2449

Leng K, Xu Y, Kang P, Qin W, Cai H, Wang H, et al. Akirin2 Is Modulated by miR-490-3p and Facilitates Angiogenesis in Cholangiocarcinoma Through the IL-6/STAT3/VEGFA Signaling Pathway. *PloS One* (2020) 15(1):1–12. doi: 10.1371/journal.pone.0191504

Pan S, Hu Y, Hu M, Xu Y, Chen M, Du C, et al. S100A8 Facilitates Cholangiocarcinoma Metastasis via Upregulation of VEGF Through TLR4–NF-κB Pathway Activation. *Int J Oncol* (2020) 56(1):101–12. doi: 10.3892/ij o.2020.4977

You Z, Bei L, Cheng LP, Cheng NS. Expression of COX-2 and VEGF-C in Cholangiocarcinomas at Different Clinical and Pathological Stages. *Gut Mol Res* (2015) 14(2):6239–46. doi: 10.4238/2015.June.9.9

Zhang J, Han C, Zhu H, Song K, Wu T. miR-101 Inhibits Cholangiocarcinoma Angiogenesis Through Targeting Vascular Endothelial Growth Factor (VEGF). *Am J Pathol* (2013) 182(5):1629–39. doi: 10.1016/j.ajpath.2013.01.2449

Leng K, Xu Y, Kang P, Qin W, Cai H, Wang H, et al. Akirin2 Is Modulated by miR-490-3p and Facilitates Angiogenesis in Cholangiocarcinoma Through the IL-6/STAT3/VEGFA Signaling Pathway. *Cell Death Dis* (2019) 10(4):1–26. doi: 10.1038/s41419-019-1506-4

Cheng R, Chen Y, Zhou H, Wang B, Du Q, Chen Y. B7-H3 Expression and Prognostic Factors in Extrahepatic Cholangiocarcinoma. *PloS One* (2014) 9(5):e97046. doi: 10.1371/journal.pone.0097046

Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal M, et al. Fibroblast Growth Factor Receptor 4 Promotes Progression and Correlates to Poor Prognosis in Cholangiocarcinoma. *Biochem Biophys Res Commun* (2014) 446(1):34–40. doi: 10.1016/j.bbrc.2014.02.050

Su WC, Shiess SC, Liu HS, Chen CY, Chow NH, Lin XZ, et al. Expression of Oncogene Products HER2/Neu and Fibroblast-Growth-Related Growth Factors BFGF, TGF-Beta, and PDGF in Bile From Biliary Malignancies and Inflammatory Disorders. *Dig Dis Sci* (2001) 46(7):1387–92. doi: 10.1023/A:1010619316436

Eyries M, Siegfried G, Cuimaras M, Montagne K, Agrapart M, Lebrun F, et al. Hypoxia-Induced Apelin Expression Regulates Endothelial Cell Proliferation and Regenerative Angiogenesis. *Circ Res* (2008) 103(4):432–40. doi: 10.1161/CIRCRESAHA.108.179333

Kidoya H, Ueno M, Yamada Y, Morizuchi N, Nakata M, Yano T, et al. Spatial and Temporal Role of the Apelin/APJ System in the Caliber Size Regulation of Blood Vessels During Angiogenesis. *EMBO J* (2008) 27(5):522–35. doi: 10.1038/emboj.2007.382

Berta J, Kenessy I, Dobos J, Tovari J, Klepetko W, Jan Ankersmit H, et al. Apelin Expression in Human Non-Small Cell Lung Cancer: Role in Angiogenesis and Prognosis. *J Thorac Oncol* (2010) 5(8):1120–9. doi: 10.1097/FTO.0b013e3182e2c1ff

Muto J, Shirabe K, Yoshizumi T, Iegami T, Aishima S, Ishigami K, et al. The Apelin-APJ System Induces Tumor Arteriogenesis in Hepatocellular Carcinoma. *Anticancer Res* (2014) 34(10):5313–20.

Hall C, Ehrlich L, Venter J, O'Brien A, White T, Zhou T, et al. Inhibition of the Apelin/Apelin Receptor Axis Decreases Cholangiocarcinoma Growth. *Cancer Lett* (2017) 386:179–88. doi: 10.1016/j.canlet.2016.11.025

Heo K, Kim YH, Sung HJ, Li HY, Yoo CW, Kim JY, et al. Hypoxia-Induced Up-Regulation of Apelin Is Associated With a Poor Prognosis in Oral Squamous Cell Carcinoma Patients. *Oral Oncol* (2012) 48(6):500–6. doi: 10.1016/j.oraloncology.2011.12.015

Diaikowska D, Markocka-Mańczak K, Szczelawski P, Grabowski K. Serum Levels of Resistin, Adiponectin, and Apelin in Gastroesophageal Cancer Patients. *Dis Markers* (2014) 2014:1–8. doi: 10.1155/2014/619649

Wan Y, Zeng ZC, Xi M, Wan S, Hua W, Liu YL, et al. Dysregulated microRNA-224/Apelin Axis Associated With Aggressive Progression and Poor Prognosis in Patients With Prostate Cancer. *Hym Pathol* (2015) 46(2):295–303. doi: 10.1016/j.humpath.2014.10.006

Aishima S, Taguchi K, Sugimachi K, Asayama Y, Nishi H, Shimada M, et al. The Role of Thymidine Phosphorylase and Thrombospondin-1 in
Wang et al. Antiangiogenic Therapy in BTCs

1. Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, et al. A Phase II Study of Sunitinib as a Second-Line Treatment in Patients With Advanced Biliary Tract Carcinoma: A Multicentre, Multinational Study. *Eur J Cancer* (2010) 46(2):196–201. doi: 10.1016/j.ejca.2011.29.15_suppl.14653

2. Dreyer C. Disease Control With Sunitinib in Advanced Intrahepatic Cholangiocarcinoma Resistant to Gemcitabine–Oxaliplatin Chemotherapy. *World J Hepatol* (2015) 7(6):910. doi: 10.4254/wjh.v7.i6.910

3. Neuzillet CSJFL. Sunitinib as Second-Line Treatment in Patients With Advanced Intrahepatic Cholangiocarcinoma (SUN-CK Phase II Trial): Safety, Efficacy, and Updated Translational Results. *J Clin Oncol* (2015) 33(3 suppl):343. doi: 10.1200/jco.2015.33.3_suppl.343

4. Bengala C, Bertolini F, Malavasi N, Boni C, Aiutti E, Dealius C, et al. Sorafenib in Patients With Advanced Biliary Tract Carcinoma: A Phase II Trial. *Br J Cancer* (2010) 102(1):68–72. doi: 10.1038/sbjc.6605458

5. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, et al. SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma. *Invest New Drugs* (2012) 30(4):1646–51. doi: 10.1007/s10637-011-9719-0

6. Morizane C, Ueno M, Nakaishi F, Mizuno N, Shimizu S. Interim Analysis of a Phase 2 Study of Lenvatinib (LEN) Monotherapy as Second-Line Treatment in Unresectable Biliary Tract Cancer (BTC). *Ann Oncol* (2017) 33(4 suppl):310. doi: 10.1093/annonc/dmx310

7. Ueno M, Ikeda M, Sasaki T, Nagashima F, Mizuno N, Shimizu S, et al. Phase 2 Study of Lenvatinib Monotherapy as Second-Line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results. *BMC Cancer* (2020) 21(1). doi: 10.1186/s12885-020-07365-4

8. Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee J, et al. A Phase 2 Trial of Regorafenib as a Single Agent in Patients With Chemotherapy-Refractory, Advanced, and Metastatic Biliary Tract Adenocarcinoma. *Cancer* (2019) 125(6):902–9. doi: 10.1002/cncr.31872

9. Iyer RV, Fokuri VK, Gromaa A, Ma WW, Malhotra U, Iancu DM, et al. A Multicenter Phase II Study of Gemcitabine, Capcitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. *Am J Clin Oncol* (2018) 41(7):649–55. doi: 10.1093/ajco/omy027

10. Zhu AX, Meyerhardt JA, Blazkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and Safety of Gemcitabine, Oxaliplatin, and Bevacizumab in Advanced Biliary-Tract Cancers and Correlation of Changes in 18-Fluorodeoxyglucose PET With Clinical Outcome: A Phase 2 Study. *Lancet Oncol* (2010) 11(1):48–54. doi: 10.1016/s1470-2045(09)70333-x

11. Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. Cediranib or Placebo in Combination With Cisplatin and Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancer (ABC-03): A Randomised Phase 2 Trial. *Lancet Oncol* (2015) 16(8):967–76. doi: 10.1016/S1470-2045(15)00139-4

12. Lee JK, Capanu M, O'Reilly EM, Ma J, Chou JF, Shia J, et al. A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Adenocarcinomas. *Br J Cancer* (2013) 109(4):915–9. doi: 10.1038/bjc.2013.432

13. Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, et al. Gemcitabine Plus Sorafenib Versus Gemcitabine Alone in Advanced Biliary Tract Cancer: A Double-Blind Placebo-Controlled Multicentre Phase II AIO Study. *Br J Cancer* (2016) 21(3):533–40. doi: 10.1038/bjc.2016.24

14. Santoro A, Gebbia V, Pressiani T, Testa A, Personeni N, Arrivas Bajardi E, et al. Randomized Phase II Crossover Trial Exploring the Clinical and Safety, Efficacy, and Updated Translational Results. *J Clin Oncol* (2015) 33(3 suppl):343. doi: 10.1200/jco.2015.33.3_suppl.343

15. Louber SJ, Mahoney MR, Kolesar JL, Locente NK, Kim GP, Pitt HC, et al. Report of a Multicenter Phase II Trial Testing a Combination of Biwweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study. *J Clin Oncol* (2010) 28(21):3491–7. doi: 10.1200/jco.2010.28.4075

16. Lin J, Yang X, Long J, Zhao S, Mao J, Wang D, et al. Pembrolizumab Combined With Lenvatinib as Non-First-Line Therapy in Patients With Refractory Biliary Tract Carcinoma. *Hepatobiliary Surg Nutr* (2020) 9(4):414–24. doi: 10.21037/hbsn-20-338

17. El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IV, Mietich KC, et al. S0941: A Phase 2 SWOG Study of Sorafenib and Erlotinib in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma. *Br J Cancer* (2014) 110(4):882–7. doi: 10.1038/bjc.2013.801
119. Oneda E, Abu HM, Zaniboni A. Biliary Tract Cancer: Current Medical Treatment Strategies. *Cancers (Basel)* (2020) 12(5). doi: 10.3390/cancers12051237

120. Qiu B, Chen T, Sun R, Liu Z, Zhang X, Li Z, et al. Sprouty4 Correlates With Favorable Prognosis in Perihilar Cholangiocarcinoma by Blocking the FGFR-ERK Signaling Pathway and Arresting the Cell Cycle. *ElBioMedicine* (2019) 50:166–77. doi: 10.1016/j.ebiom.2019.11.021

121. Li Z, Liu J, Chen T, Sun R, Liu Z, Qiu B, et al. HMGA1-TRIP13 Axis Promotes Stemness and Epithelial Mesenchymal Transition of Perihilar Cholangiocarcinoma in a Positive Feedback Loop Dependent on C-Myc. *J Exp Clin Cancer Res* (2021) 40(1):86. doi: 10.1186/s13046-021-01890-1

122. Liu Z, Sun R, Zhang X, Qiu B, Chen T, Li Z, et al. Transcription Factor 7 Promotes the Progression of Perihilar Cholangiocarcinoma by Inducing the Transcription of C-Myc and FOS-Like Antigen 1. *ElBioMedicine* (2019) 45:181–91. doi: 10.1016/j.ebiom.2019.06.023

123. Sun R, Liu Z, Qiu B, Chen T, Li Z, Zhang X, et al. Annexin10 Promotes Extrahepatic Cholangiocarcinoma Metastasis by Facilitating EMT via PLA2G4A/PGE2/STAT3 Pathway. *ElBioMedicine* (2019) 47:142–55. doi: 10.1016/j.ebiom.2019.08.062

124. Vaeteewoottacharn K, Kariya R, Dana P, Fujikawa S, Matsuda K, Ohkuma K, et al. Inhibition of Carbonic Anhydrase Potentiates Bevacizumab Treatment in Cholangiocarcinoma. *Tumor Biol* (2016) 37(7):9023–35. doi: 10.1007/s13277-016-4785-8

125. Meyer H, Wienke A, Surow A. Association Between VEGF Expression and Diffusion Weighted Imaging in Several Tumors—A Systematic Review and Meta-Analysis. *Diagnostics* (2019) 9(4):126. doi: 10.3390/diagnostics9040126

126. Weis SM, Cheresh DA. Tumor Angiogenesis: Molecular Pathways and Therapeutic Targets. *Nat Med* (2011) 17(11):1359–70. doi: 10.1038/nm.2537

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer ZL declared a shared affiliation, with no collaboration, with TC to the handling editor at the time of review.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Chen, Li, Mu, Liu, Shi, Liu, Zhao, Lian, Huang, Pan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.